Skip to main content

Table 1 Baseline characteristics of HIV-infected participants enrolled in a randomized trial comparing directly administered antiretroviral therapy to self administered therapy in opioid treatment programs, Baltimore, Maryland.

From: Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs

Characteristic Enrolled in studya(n = 107) Declined to participatea(n = 12)
Opioid treatment program (enrollment site)   
   1 39 (36) 2 (17)
   2 35 (33) 1 (8)
   3 8 (8) 0
   4 14 (13) 9 (75)
   5 11 (10) 0
Female 51 (48) 7 (58)
Race   
   African American 88 (82) 7 (58)
   Caucasian/other 19 (18) 5 (42)
Age, years 47 (41-51) 46 (38-51)
Education   
   Less than high school graduate 51 (48)  
   High school graduate or equivalent 36 (34)  
   Any college, n (%) 20 (19)  
Marital status   
   Married or live with partner 17 (16)  
   Never married 54 (51)  
   Widowed 9 (8)  
   Divorced or separated 27 (25)  
Considers himself/herself to be homeless 32 (30)  
Housing/living situation   
   Own a house 3 (3)  
   Rent an apartment/house 49 (46)  
   Stay with family or friends 35 (33)  
   Residential drug treatment 5 (5)  
   Other residential facility or institution 11 (10)  
   Live on street or in single room occupancy hotel 4 (4)  
Employed 16 (15)  
Duration of methadone or buprenorphine treatment, months 11 (2-49)  
Receiving methadone 99 (93)  
   Methadone dose, mg 90 (70-120)  
Receiving buprenorphine 8 (7)  
   Buprenorphine dose, mg 19 (14-27)  
Depression scoreb 11 (5-15)  
Urine drug test, positive results   
   Cocaine 42 (40)c  
   Benzodiazepine 14 (13)c  
   Opiate (morphine/codeine) 21 (20)c  
   Oxycodone 1 (1)c  
Nadir CD4 count, cells/mm3 102 (30-218)  
Current CD4 count, cells/mm3 182 (69-309)  
HIV RNA log10 copies/mL 4.7 (4.0-5.1)  
Hospitalized in prior 3 months 34 (32)  
Prior AIDS-defining opportunistic condition 66 (62)  
Hepatitis C antibody positive 87 (81)  
Antiretroviral naive 21 (20)  
Category of prescribed antiretroviral regimen   
   PI + NRTIs 83 (78)  
   NNRTI + NRTIs 16 (15)  
   NRTIs only 1 (1)  
   Other 7 (7)  
Drug classes included in antiretroviral regimen (not mutually exclusive)   
   NRTI 97 (91)  
   Ritonavir-boosted PI 85 (79)  
   PI (not boosted with ritonavir) 4 (4)  
   NNRTI 21 (20)  
   Integrase inhibitor 7 (7)  
Dosing frequency of prescribed antiretroviral regimen   
   Once daily 65 (61)  
   Twice daily 42 (39)  
  1. PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
  2. a Values are frequency (%) or median (interquartile range)
  3. b Center for Epidemiologic Studies Depression (CES-D) Scale (7). Higher values indicate more numerous or more severe depressive symptoms (range 0 to 30).
  4. c From 106 subjects.